| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2140426 | Lung Cancer | 2016 | 4 Pages |
Abstract
Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Janine Doesch, Dirk Debus, Christian Meyer, Thomas Papadopoulos, Erwin S Schultz, Joachim H. Ficker, Wolfgang M. Brueckl,